Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report.

Golubchik P, Sever J, Weizman A, Zalsman G.

Clin Neuropharmacol. 2011 May-Jun;34(3):108-10. doi: 10.1097/WNF.0b013e31821f4da9.

PMID:
21586916
2.

Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.

Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):179-82. doi: 10.1097/WNF.0b013e318183796d.

PMID:
19644227
3.

Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.

Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.

Sleep Med. 2007 Jan;8(1):18-30. Epub 2006 Dec 6.

PMID:
17157069
4.
5.

Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial.

Golubchik P, Sever J, Zalsman G, Weizman A.

Int Clin Psychopharmacol. 2008 Jul;23(4):228-31. doi: 10.1097/YIC.0b013e3282f94ae2.

PMID:
18446088
6.

Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.

Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.

Chin Med J (Engl). 2011 Oct;124(20):3269-74.

PMID:
22088519
7.

When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.

Manor I, Rozen S, Zemishlani Z, Weizman A, Zalsman G.

Clin Neuropharmacol. 2011 Jul-Aug;34(4):148-54. doi: 10.1097/WNF.0b013e3182206dc1.

PMID:
21738027
8.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
9.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

10.

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.

Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.

Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.

PMID:
21904084
11.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
12.

Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.

Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M, Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz L; RUPP ADHD/Anxiety Study Group.

J Am Acad Child Adolesc Psychiatry. 2005 May;44(5):418-27.

PMID:
15843763
13.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
14.

Variability of response time as a predictor of methylphenidate treatment response in korean children with attention deficit hyperactivity disorder.

Lee SH, Song DH, Kim BN, Joung YS, Ha EH, Cheon KA, Shin YJ, Yoo HJ, Shin DW.

Yonsei Med J. 2009 Oct 31;50(5):650-5. doi: 10.3349/ymj.2009.50.5.650. Epub 2009 Oct 21.

15.

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.

Can J Clin Pharmacol. 2006 Winter;13(1):e50-62. Epub 2006 Jan 23.

PMID:
16456216
16.

Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD.

Biederman J, Mick E, Spencer T, Surman C, Faraone SV.

CNS Neurosci Ther. 2012 Feb;18(2):126-32. doi: 10.1111/j.1755-5949.2010.00233.x. Epub 2011 Aug 5.

PMID:
22070421
17.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.

PMID:
21787126
18.

Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.

Levin FR, Evans SM, Brooks DJ, Garawi F.

Drug Alcohol Depend. 2007 Feb 23;87(1):20-9. Epub 2006 Aug 22.

PMID:
16930863
19.

The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.

Golubchik P, Golubchik L, Sever JM, Weizman A.

Int Clin Psychopharmacol. 2014 Sep;29(5):274-8. doi: 10.1097/YIC.0000000000000034.

PMID:
24743562
20.

Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?

Golubchik P, Kodesh A, Weizman A.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):141-5. doi: 10.1097/WNF.0b013e31829eb204.

PMID:
24045603

Supplemental Content

Support Center